Foot drop in patients treated with bortezomib–a case series and review of the literature

Iuliana Vaxman; Michelle L. Mauerman; Moshe L. Gatt; Tamar Berger; Morie A. Gertz

doi:10.1080/10428194.2021.1992758

Foot drop in patients treated with bortezomib–a case series and review of the literature

Iuliana Vaxman^*, Michelle L. Mauerman, Moshe L. Gatt, Tamar Berger, Morie A. Gertz

^*Corresponding author for this work

Faculty of Medicine

Research output: Contribution to journal › Article › peer-review

5 Scopus citations

Abstract

Bortezomib-induced peripheral neuropathy (BIPN) has a profound impact on quality of life, which is an important issue considering the growing number of survivors of multiple myeloma and amyloidosis. BIPN is typically symmetric, distal, "stocking and glove" distribution and predominantly consists of sensory rather than motor symptoms. In this case series, we report an acute neurotoxicity syndrome induced by bortezomib, which is clinically distinct from BIPN by not being peripheral and distal. We describe six patients that developed unilateral or bilateral foot drop attributed to bortezomib. With bortezomib discontinuation symptoms improved gradually over months to years.

Original language	English
Pages (from-to)	722-728
Number of pages	7
Journal	Leukemia and Lymphoma
Volume	63
Issue number	3
DOIs	https://doi.org/10.1080/10428194.2021.1992758
State	Published - 2022

Bibliographical note

Publisher Copyright:
© 2021 Informa UK Limited, trading as Taylor & Francis Group.

Keywords

Foot drop
amyloidosis
bortezomib
multiple myeloma
neuropathy
peroneal nerve palsy
Multiple Myeloma/complications
Humans
Peripheral Nervous System Diseases/chemically induced
Bortezomib/adverse effects
Quality of Life
Antineoplastic Agents/adverse effects
Peroneal Neuropathies/chemically induced

Access to Document

10.1080/10428194.2021.1992758

Cite this

@article{89892843cd7043458032577fd1853f49,

title = "Foot drop in patients treated with bortezomib–a case series and review of the literature",

abstract = "Bortezomib-induced peripheral neuropathy (BIPN) has a profound impact on quality of life, which is an important issue considering the growing number of survivors of multiple myeloma and amyloidosis. BIPN is typically symmetric, distal, {"}stocking and glove{"} distribution and predominantly consists of sensory rather than motor symptoms. In this case series, we report an acute neurotoxicity syndrome induced by bortezomib, which is clinically distinct from BIPN by not being peripheral and distal. We describe six patients that developed unilateral or bilateral foot drop attributed to bortezomib. With bortezomib discontinuation symptoms improved gradually over months to years.",

keywords = "Foot drop, amyloidosis, bortezomib, multiple myeloma, neuropathy, peroneal nerve palsy, Multiple Myeloma/complications, Humans, Peripheral Nervous System Diseases/chemically induced, Bortezomib/adverse effects, Quality of Life, Antineoplastic Agents/adverse effects, Peroneal Neuropathies/chemically induced",

author = "Iuliana Vaxman and Mauerman, {Michelle L.} and Gatt, {Moshe L.} and Tamar Berger and Gertz, {Morie A.}",

note = "Publisher Copyright: {\textcopyright} 2021 Informa UK Limited, trading as Taylor & Francis Group.",

year = "2022",

doi = "10.1080/10428194.2021.1992758",

language = "אנגלית",

volume = "63",

pages = "722--728",

journal = "Leukemia and Lymphoma",

issn = "1042-8194",

publisher = "Informa Healthcare",

number = "3",

}

TY - JOUR

T1 - Foot drop in patients treated with bortezomib–a case series and review of the literature

AU - Vaxman, Iuliana

AU - Mauerman, Michelle L.

AU - Gatt, Moshe L.

AU - Berger, Tamar

AU - Gertz, Morie A.

PY - 2022

Y1 - 2022

N2 - Bortezomib-induced peripheral neuropathy (BIPN) has a profound impact on quality of life, which is an important issue considering the growing number of survivors of multiple myeloma and amyloidosis. BIPN is typically symmetric, distal, "stocking and glove" distribution and predominantly consists of sensory rather than motor symptoms. In this case series, we report an acute neurotoxicity syndrome induced by bortezomib, which is clinically distinct from BIPN by not being peripheral and distal. We describe six patients that developed unilateral or bilateral foot drop attributed to bortezomib. With bortezomib discontinuation symptoms improved gradually over months to years.

AB - Bortezomib-induced peripheral neuropathy (BIPN) has a profound impact on quality of life, which is an important issue considering the growing number of survivors of multiple myeloma and amyloidosis. BIPN is typically symmetric, distal, "stocking and glove" distribution and predominantly consists of sensory rather than motor symptoms. In this case series, we report an acute neurotoxicity syndrome induced by bortezomib, which is clinically distinct from BIPN by not being peripheral and distal. We describe six patients that developed unilateral or bilateral foot drop attributed to bortezomib. With bortezomib discontinuation symptoms improved gradually over months to years.

KW - Foot drop

KW - amyloidosis

KW - bortezomib

KW - multiple myeloma

KW - neuropathy

KW - peroneal nerve palsy

KW - Multiple Myeloma/complications

KW - Humans

KW - Peripheral Nervous System Diseases/chemically induced

KW - Bortezomib/adverse effects

KW - Quality of Life

KW - Antineoplastic Agents/adverse effects

KW - Peroneal Neuropathies/chemically induced

UR - http://www.scopus.com/inward/record.url?scp=85118255481&partnerID=8YFLogxK

U2 - 10.1080/10428194.2021.1992758

DO - 10.1080/10428194.2021.1992758

M3 - ???researchoutput.researchoutputtypes.contributiontojournal.article???

C2 - 34702127

AN - SCOPUS:85118255481

SN - 1042-8194

VL - 63

SP - 722

EP - 728

JO - Leukemia and Lymphoma

JF - Leukemia and Lymphoma

IS - 3

ER -

Foot drop in patients treated with bortezomib–a case series and review of the literature

Abstract

Bibliographical note

Keywords

Access to Document

Other files and links

Fingerprint

Cite this